Refer to latest NICE guidance, TAG217, March 2011 (updated May 2016). Only specialists should initiate treatment after formal |
assessment including tests of cognitive, global and behavioural functioning and the likelihood of the patient to comply with |
therapy. GPs may be asked to take over prescribing once an appropriate maintenance dose has been reached and the patient has |
been demonstrated to benefit from therapy. Patients continuing on treatment should be assessed every six months in secondary |
care. |
|
AMBER Generic Donepezil (1st line use) |
tablets and orodispersible tablets 5mg, 10mg |
NB Orodispersible tablets should be reserved for use in those with swallowing difficulties only. |
(Dispersible tablets are more cost effective compared to liquid preparations) |
|
AMBER Galantamine modified release tablets 8mg, 16mg, 24mg |
Preferred formulary choices are Gatalin® XL tablets, Luventa® XL tablets |
(Prescribe by brand) |
(Please note standard release tablets or liquid preparations are not approved for use in EL & BwD CCG and should not be prescribed in |
Primary Care) |
|
AMBER Rivastigmine |
capsules 1.5mg, 3mg, 4.5mg |
solution 10mg/5mL |
patches 4.6mg/24 hours, 9.5mg/24 hours |
NB patches should be reserved for those patients who are unable to tolerate or swallow an AChEI. |
|
AMBER Memantine (3rd lne choice) |
tablets 10mg, 20mg |
oral solution 10mg/mL |
orodispersible tablets 10mg, 20mg |
|
A prescribing information sheet for these drugs can be found here |
|
|
|
|
All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the |
public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service. |
Email: info.elmmb@nhs.net |
Copyright© 2016 East Lancashire Medicines Management Board |
All rights reserved. Disclaimer/Terms and conditions |
|
|